Crigler–Najjar Syndrome Market Crigler–Najjar syndrome is rare genetic liver disorder characterized by abnormal accumulation of bilirubin, a yellow pigment produced by the liver. This accumulation is caused by deficiency of the enzyme called UGT1A1. This enzyme is responsible for the conversion of bilirubin into a substance that can be eliminated. Crigler–Najjar Syndrome can cause significant neurological damage.

According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual prevalence of Crigler-Najjar syndrome is 1 in one million newborns worldwide. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth

Market Drivers

Huge financial support to the researchers for developing novel intervention is boosting the market growth

Increase in demand of disease specific novel treatment can also act as a market driver

Family history of Crigler–Najjar syndrome is driving the growth of the market

Increase in special designation from the regulatory authorities is drive the market

Get Exclusive Sample Report: @

 Scope of the Crigler–Najjar Syndrome Market

  • Current and future of Crigler–Najjar Syndrome Market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Global Crigler–Najjar Syndrome Market  By Treatment (Medication, Surgery), Drugs (Bilirubin Chelators, Ursodeoxycholic Acid and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

 Browse Related Report  Here:

Asia-Pacific Dermatology Drugs Market

Rheumatoid Arthritis Market

Some of the leading key players profiled in this study:

Few of the major competitors currently working in the global Crigler–Najjar syndrome market are International Stem Cell Corporation, Promethera, Selecta Biosciences, Inc, LOGICBIO THERAPEUTICS, INC, Genethon, Audentes Therapeutics, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett and others

 Get Detailed Toc and Charts & Tables

Key Pointers Covered in the Crigler–Najjar Syndrome Market Trends and Forecast to 2026

    • Crigler–Najjar Syndrome Market New Sales Volumes
    • Crigler–Najjar Syndrome Market Replacement Sales Volumes
    • Crigler–Najjar Syndrome Market Installed Base
    • Crigler–Najjar Syndrome Market By Brands
    • Crigler–Najjar Syndrome Market Size
    • Crigler–Najjar Syndrome Market Procedure Volumes
    • Crigler–Najjar Syndrome Market Product Price Analysis
    • Crigler–Najjar Syndrome Market Healthcare Outcomes
    • Crigler–Najjar Syndrome Market Cost of Care Analysis
    • Crigler–Najjar Syndrome Market Regulatory Framework and Changes
    • Crigler–Najjar Syndrome Market Prices and Reimbursement Analysis
    • Crigler–Najjar Syndrome Market Shares in Different Regions
    • Recent Developments for Crigler–Najjar Syndrome Market Competitors
    • Crigler–Najjar Syndrome Market Upcoming Applications
    • Crigler–Najjar Syndrome Market Innovators Study

Inquiry before Buying @

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market


Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]